Such an invasive growth controlling role of FBLN2 would further be explained by the improved DMFS rate for breast cancer patients with LN negative or intermediate to low grade breast cancer, where the level of progression from DCIS to invasive growth could be the distinguishing factor. This evidence concerns the gene FBLN2 and breast carcinoma.